- Poland
- /
- Medical Equipment
- /
- WSE:BMX
BioMaxima Third Quarter 2023 Earnings: zł0.09 loss per share (vs zł0.22 profit in 3Q 2022)
BioMaxima (WSE:BMX) Third Quarter 2023 Results
Key Financial Results
- Revenue: zł11.5m (down 12% from 3Q 2022).
- Net loss: zł366.0k (down by 139% from zł933.0k profit in 3Q 2022).
- zł0.09 loss per share (down from zł0.22 profit in 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BioMaxima's share price is broadly unchanged from a week ago.
Risk Analysis
Before you take the next step you should know about the 4 warning signs for BioMaxima (2 are concerning!) that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if BioMaxima might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:BMX
BioMaxima
Manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland.
Excellent balance sheet slight.